"Tryptyr Eye Drops (Acoltremon 0.003%): FDA-Approved Treatment for Dry Eye Disease with Fast Relief"

 

Tryptyr is a first-in-class prescription eye drop containing the active compound acoltremon (0.003%), developed by Alcon. It was approved by the U.S. FDA in May 2025 for the treatment of signs and symptoms of dry eye disease (DED)  a chronic condition affecting millions globally.

Unlike traditional therapies, Tryptyr uses a novel neuromodulatory approach, stimulating the eye's natural tear production mechanisms without relying on immunosuppressants.

---

Mechanism of Action

Tryptyr is a TRPM8 (Transient Receptor Potential Melastatin 8) agonist, which:

·         Activates cold-sensitive receptors on the cornea

·         Stimulates trigeminal sensory pathways

·         Promotes natural tear production

This unique mechanism offers rapid symptom relief and is particularly effective for patients whose DED is driven by decreased tear production rather than inflammation.

---

Clinical Trial Evidence

COMET-2 and COMET-3 Trials:

·         Involved over 900 patients with moderate-to-severe dry eye disease

·         Showed statistically significant improvement in tear production (Schirmer test)

·         Day 14 response rates:

o    COMET-2: 42.6% (Tryptyr) vs. 8.2% (placebo)

o    COMET-3: 53.2% (Tryptyr) vs. 14.4% (placebo)

·         Effect sustained through 90 days

Conclusion: Tryptyr delivers fast, clinically meaningful relief, especially for tear-deficient DED cases.

---

Dosing & Administration

·         Dosage: 1 drop in each eye, twice daily (approximately 12 hours apart)

·         Form: Sterile single-use vials

·         Storage:

o    Refrigerate sealed pouches

o    After opening, use vials within:

-7 days (if stored at room temperature)

-30 days (if refrigerated)

Quick Tips for Use:

·         Wash hands before use

·         Remove contact lenses before instillation

·         Wait at least 15 minutes before reinserting lenses

·         Do not touch dropper tip to eye or surfaces

---

Side Effects & Safety

Common Side Effects (seen in up to 50% users):

·         Instillation-site pain, burning, or stinging

·         Temporary blurred vision

Rare/Serious Reactions:

·         Eye redness, irritation, or swelling

·         Vision changes or infection symptoms

No known systemic absorption risks.
No contraindications listed.

Caution: Always consult an ophthalmologist if symptoms worsen or systemic signs appear.

---

Tryptyr vs. Other Dry Eye Treatments

Feature	Tryptyr	Cyclosporine (Restasis)	Lifitegrast (Xiidra)
Mode of action	TRPM8 neuromodulation	Anti-inflammatory	Anti-inflammatory
Onset of relief	Rapid (within 1–2 days)	Weeks to months	Weeks
Contact lens safety	Remove before use	Remove before use	Remove before use
Prescription required	✅ Yes	✅ Yes	✅ Yes
Burning sensation	Moderate	Common	Common

Tryptyr offers a non-immunosuppressive alternative, making it suitable for patients with chronic dry eye symptoms not driven by inflammation.

---

Market Availability

·         FDA Approved: May 28, 2025

·         Expected US launch: Q3 2025

·         Manufacturer: Alcon Inc.

·         Global Expansion: Awaiting EMA and other regulatory clearances

---

Who Should Consider Tryptyr?

Ideal for:

·         Patients with aqueous-deficient dry eye

·         Individuals not responding to current anti-inflammatory drops

·         Contact lens wearers (with precautions)

·         Adults with chronic tear deficiency

Not recommended for:

·         Children (safety not established)

·         Patients allergic to acoltremon components

---

Final Insight

Tryptyr represents a paradigm shift in dry eye therapy, addressing root tear production issues through cold receptor stimulation rather than inflammation suppression. With its rapid onset, minimal systemic risk, and well-tolerated profile, it’s a strong candidate for first-line or adjunct treatment of moderate-to-severe dry eye disease.